Answers are grounded in this paper and cite their sources.
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in which amyloid-β, tau pathology, synaptic dysfunction, and neuroinflammation interact across molecular, cellular, and network levels. Although these processes are well established individually, their reciprocal and stage-dependent relationships remain insufficiently integrated into a unified mechanistic framework. Age-related decline in proteostatic, metabolic, vascular, and immune resilience may further lower the threshold at which these interacting pathways become self-sustaining. This review therefore examines how protein aggregation, neuronal stress, and glial responses converge to shape disease progression. Summary: Amyloid-β oligomerization can disrupt synaptic signaling and calcium homeostasis, creating conditions that promote tau-directed kinase activation, tau hyperphosphorylation, mislocalization, and propagation. Pathological tau further compromises microtubule stability, axonal transport, synaptic function, and neuronal resilience. In parallel, microglial and astrocytic responses influence amyloid clearance, inflammatory signaling, blood-brain barrier integrity, and neuronal injury through pathways that include TREM2 and the NLRP3 inflammasome. These interactions generate feedback loops in which impaired clearance, proteinopathy, synaptic stress, and chronic inflammation can reinforce one another, while their relative contribution may vary across disease stages and individuals.Conclusion: Here we highlight AD as a dynamic mechanistic network rather than a fixed single-pathway cascade. The proposed framework distinguishes disease initiation from subsequent pathway dominance and amplification. Integrating amyloid, tau, synaptic, and neuroimmune processes may improve interpretation of disease heterogeneity, support multimodal biomarker strategies, and inform stage-matched therapeutic combinations. This framework also identifies causal direction, pathway dominance, and temporal transitions as priorities for future mechanistic and clinical research.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: